Foghorn Therapeutics (FHTX) Common Equity (2019 - 2026)

Foghorn Therapeutics' Common Equity history runs 8 years deep, the most recent figure standing at -$76.4 million for Q1 2026.

• In Q1 2026, Common Equity fell 23.93% year-over-year to -$76.4 million; the TTM figure through Mar 2026 stood at -$76.4 million (down 23.93% YoY), while the FY2025 annual figure was -$108.5 million, down 138.31% from the prior year.
• Common Equity was -$76.4 million for Q1 2026 at Foghorn Therapeutics, up from -$108.5 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $72.4 million in Q1 2022 to a low of -$108.5 million in Q4 2025.
• Historically, Common Equity has averaged -$39.0 million across 5 years, with a median of -$49.3 million in 2023.
• The sharpest annual moves came in 2023 and 2024: Common Equity sank 69019.64% in 2023, then surged 70.98% in 2024.
• A 5-year view of Common Equity shows it stood at $112000.0 in 2022, then tumbled by 69019.64% to -$77.2 million in 2023, then surged by 41.02% to -$45.5 million in 2024, then plunged by 138.31% to -$108.5 million in 2025, then advanced by 29.58% to -$76.4 million in 2026.
• The last three Common Equity figures came in at -$76.4 million (Q1 2026), -$108.5 million (Q4 2025), and -$89.7 million (Q3 2025), per Business Quant data.